Sandbox: sadaf: Difference between revisions

Jump to navigation Jump to search
Ssharfaei (talk | contribs)
Ssharfaei (talk | contribs)
Line 26: Line 26:
! rowspan="14" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet disorders
! rowspan="14" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet disorders
! rowspan="7" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombocytopenia]]
! rowspan="7" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombocytopenia]]
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Infection]]-Induced [[thrombocytopenia]]<span name="harr_c115s002s001s002p001"></span><span name="9100754"></span><ref name="pmid21325604">{{cite journal |vauthors=Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA |title=The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia |journal=Blood |volume=117 |issue=16 |pages=4190–207 |date=April 2011 |pmid=21325604 |doi=10.1182/blood-2010-08-302984 |url=}}</ref><ref name="pmid26906627">{{cite journal |vauthors=Karimi O, Goorhuis A, Schinkel J, Codrington J, Vreden SGS, Vermaat JS, Stijnis C, Grobusch MP |title=Thrombocytopenia and subcutaneous bleedings in a patient with Zika virus infection |journal=Lancet |volume=387 |issue=10022 |pages=939–940 |date=March 2016 |pmid=26906627 |doi=10.1016/S0140-6736(16)00502-X |url=}}</ref><ref name="pmid25600600">{{cite journal |vauthors=Zammarchi L, Stella G, Mantella A, Bartolozzi D, Tappe D, Günther S, Oestereich L, Cadar D, Muñoz-Fontela C, Bartoloni A, Schmidt-Chanasit J |title=Zika virus infections imported to Italy: clinical, immunological and virological findings, and public health implications |journal=J. Clin. Virol. |volume=63 |issue= |pages=32–5 |date=February 2015 |pmid=25600600 |doi=10.1016/j.jcv.2014.12.005 |url=}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Infection]]-Induced [[thrombocytopenia]]<span name="harr_c115s002s001s002p001"></span><span name="9100754"></span>
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* History of prior infection
* History of prior infection
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
Line 42: Line 42:
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Medication|Medications]]-Induced [[Thrombocytopenia|thrombocy]]<span name="harr_c115s002s001s003p001"></span><span name="9100757"></span>[[Thrombocytopenia|topenia]] <ref name="pmid25134884">{{cite journal |vauthors=Kam T, Alexander M |title=Drug-induced immune thrombocytopenia |journal=J Pharm Pract |volume=27 |issue=5 |pages=430–9 |date=October 2014 |pmid=25134884 |doi=10.1177/0897190014546099 |url=}}</ref><ref name="pmid23461497">{{cite journal |vauthors=Seco-Melantuche R, Delgado-Sánchez O, Álvarez-Arroyo L |title=[Incidence of drug-induced thrombocytopenia in hospitalized patients] |language=Spanish; Castilian |journal=Farm Hosp |volume=37 |issue=1 |pages=27–34 |date=2013 |pmid=23461497 |doi=10.7399/FH.2013.37.1.42 |url=}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Medication|Medications]]-Induced [[Thrombocytopenia|thrombocy]]<span name="harr_c115s002s001s003p001"></span><span name="9100757"></span>[[Thrombocytopenia|topenia]]  
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
*History of [[Medication|medications]] such as:
*History of [[Medication|medications]] such as:
Line 54: Line 54:
** [[Linezolid]]  
** [[Linezolid]]  
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |+
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
Line 66: Line 66:
| align="center" style="background:#F5F5F5;" | Most important part of treatment is discontinuing of the medication.
| align="center" style="background:#F5F5F5;" | Most important part of treatment is discontinuing of the medication.
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Heparin-Induced Thrombocytopenia|Heparin-Induced thrombocytopenia]]<span name="harr_c115s002s001s004p001"></span><span name="9100761"></span><ref name="pmid25629757">{{cite journal |vauthors=Warkentin TE, Safyan EL, Linkins LA |title=Heparin-induced thrombocytopenia presenting as bilateral adrenal hemorrhages |journal=N. Engl. J. Med. |volume=372 |issue=5 |pages=492–4 |date=January 2015 |pmid=25629757 |doi=10.1056/NEJMc1414161 |url=}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Heparin-Induced Thrombocytopenia|Heparin-Induced thrombocytopenia]]<span name="harr_c115s002s001s004p001"></span><span name="9100761"></span>
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* [[Thrombosis]]
* [[Thrombosis]]
Line 83: Line 83:
| align="center" style="background:#F5F5F5;" | For more information click here: [[Heparin-induced thrombocytopenia]].  
| align="center" style="background:#F5F5F5;" | For more information click here: [[Heparin-induced thrombocytopenia]].  
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Idiopathic thrombocytopenic purpura|Immune Thrombocytopenic Purpura]] ([[Idiopathic thrombocytopenic purpura|ITP]])<span name="harr_c115s002s001s005p001"></span><span name="9100771"></span><ref name="pmid8857953">{{cite journal |vauthors=Wright JF, Blanchette VS, Wang H, Arya N, Petric M, Semple JW, Chia WK, Freedman J |title=Characterization of platelet-reactive antibodies in children with varicella-associated acute immune thrombocytopenic purpura (ITP) |journal=Br. J. Haematol. |volume=95 |issue=1 |pages=145–52 |date=October 1996 |pmid=8857953 |doi= |url=}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Idiopathic thrombocytopenic purpura|Immune Thrombocytopenic Purpura]] ([[Idiopathic thrombocytopenic purpura|ITP]])<span name="harr_c115s002s001s005p001"></span><span name="9100771"></span>
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* History of prior [[infection]] or no history
* History of prior [[infection]] or no history
Line 99: Line 99:
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited [[Thrombocytopenia]]<span name="harr_c115s002s001s006p001"></span><span name="9100783"></span><ref name="pmid27025194">{{cite journal |vauthors=Johnson B, Fletcher SJ, Morgan NV |title=Inherited thrombocytopenia: novel insights into megakaryocyte maturation, proplatelet formation and platelet lifespan |journal=Platelets |volume=27 |issue=6 |pages=519–25 |date=September 2016 |pmid=27025194 |pmc=5000870 |doi=10.3109/09537104.2016.1148806 |url=}}</ref><ref name="pmid30103613">{{cite journal |vauthors=Wang Q, Cao L, Sheng G, Shen H, Ling J, Xie J, Ma Z, Yin J, Wang Z, Yu Z, Chen S, Zhao Y, Ruan C, Xia L, Jiang M |title=Application of High-Throughput Sequencing in the Diagnosis of Inherited Thrombocytopenia |journal=Clin. Appl. Thromb. Hemost. |volume= |issue= |pages=1076029618790696 |date=August 2018 |pmid=30103613 |doi=10.1177/1076029618790696 |url=}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited [[Thrombocytopenia]]<span name="harr_c115s002s001s006p001"></span><span name="9100783"></span>
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* Positive family history
* Positive family history
Line 115: Line 115:
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombotic thrombocytopenic purpura|Thrombotic Thrombocytopenic Purpura]] ([[Thrombotic thrombocytopenic purpura|TTP]])<span name="harr_c115s002s002s001p001"></span><span name="9100787"></span><ref name="pmid30220931">{{cite journal |vauthors=Knöbl P |title=Thrombotic thrombocytopenic purpura |journal=Memo |volume=11 |issue=3 |pages=220–226 |date=2018 |pmid=30220931 |doi=10.1007/s12254-018-0429-6 |url=}}</ref><ref name="pmid26386489">{{cite journal |vauthors=Mannucci PM, Cugno M |title=The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring |journal=Thromb. Res. |volume=136 |issue=5 |pages=851–4 |date=November 2015 |pmid=26386489 |doi=10.1016/j.thromres.2015.09.007 |url=}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombotic thrombocytopenic purpura|Thrombotic Thrombocytopenic Purpura]] ([[Thrombotic thrombocytopenic purpura|TTP]])<span name="harr_c115s002s002s001p001"></span><span name="9100787"></span>
| align="left" style="background:#F5F5F5;" | History of:
| align="left" style="background:#F5F5F5;" | History of:
*[[Cancer]]
*[[Cancer]]
Line 137: Line 137:
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemolytic-uremic syndrome|Hemolytic Uremic Syndrome]]<span name="harr_c115s002s002s002p001"></span><span name="9100796"></span><ref name="pmid24365375">{{cite journal |vauthors=Webster K, Schnitzler E |title=Hemolytic uremic syndrome |journal=Handb Clin Neurol |volume=120 |issue= |pages=1113–23 |date=2014 |pmid=24365375 |doi=10.1016/B978-0-7020-4087-0.00075-9 |url=}}</ref><ref name="pmid25845294">{{cite journal |vauthors=Picard C, Burtey S, Bornet C, Curti C, Montana M, Vanelle P |title=Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome |journal=Pathol. Biol. |volume=63 |issue=3 |pages=136–43 |date=June 2015 |pmid=25845294 |doi=10.1016/j.patbio.2015.03.001 |url=}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemolytic-uremic syndrome|Hemolytic Uremic Syndrome]]<span name="harr_c115s002s002s002p001"></span><span name="9100796"></span>
| align="left" style="background:#F5F5F5;" |History of:
| align="left" style="background:#F5F5F5;" |History of:
* [[Infections]]
* [[Infections]]
Line 207: Line 207:
* Diminished for GP 2B-3A on [[Flow cytometry|flow cytometry]]  
* Diminished for GP 2B-3A on [[Flow cytometry|flow cytometry]]  
|-
|-
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Bernard-Soulier syndrome]]<ref name="pmid30077511">{{cite journal |vauthors=Dupuis A, Gachet C |title=Inherited platelet disorders : Management of the bleeding risk |journal=Transfus Clin Biol |volume=25 |issue=3 |pages=228–235 |date=September 2018 |pmid=30077511 |doi=10.1016/j.tracli.2018.07.003 |url=}}</ref><ref name="pmid29227167">{{cite journal |vauthors=Andres O, Henning K, Strauß G, Pflug A, Manukjan G, Schulze H |title=Diagnosis of platelet function disorders: A standardized, rational, and modular flow cytometric approach |journal=Platelets |volume=29 |issue=4 |pages=347–356 |date=June 2018 |pmid=29227167 |doi=10.1080/09537104.2017.1386297 |url=}}</ref>
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Bernard-Soulier syndrome]]
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* Positive family history
* Positive family history
Line 227: Line 227:
* Ristocetin - no aggregation
* Ristocetin - no aggregation
|-
|-
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Wiskott-Aldrich syndrome]]<ref name="pmid23527934">{{cite journal |vauthors=Wang YQ, Cui YX, Feng J |title=[Clinical phenotype and gene diagnostic analysis of Omenn syndrome] |language=Chinese |journal=Zhonghua Er Ke Za Zhi |volume=51 |issue=1 |pages=64–8 |date=January 2013 |pmid=23527934 |doi= |url=}}</ref><ref name="pmid27340577">{{cite journal |vauthors=Patil RB, Shanmukhaiah C, Jijina F, Bamborde S, Wasekar N, Toshniwal M, Mohite A, Patil V |title=Wiskott-Aldrich Syndrome Presenting with JMML-Like Blood Picture and Normal Sized Platelets |journal=Case Rep Hematol |volume=2016 |issue= |pages=8230786 |date=2016 |pmid=27340577 |pmc=4906177 |doi=10.1155/2016/8230786 |url=}}</ref><ref name="pmid29348920">{{cite journal |vauthors=Kaneko R, Yamamoto S, Okamoto N, Akiyama K, Matsuno R, Toyama D, Hoshino A, Imai K, Isoyama K |title=Wiskott-Aldrich syndrome that was initially diagnosed as immune thrombocytopenic purpura secondary to a cytomegalovirus infection |journal=SAGE Open Med Case Rep |volume=6 |issue= |pages=2050313X17753788 |date=2018 |pmid=29348920 |pmc=5768273 |doi=10.1177/2050313X17753788 |url=}}</ref><ref name="pmid19084106">{{cite journal |vauthors=Ozcan E, Notarangelo LD, Geha RS |title=Primary immune deficiencies with aberrant IgE production |journal=J. Allergy Clin. Immunol. |volume=122 |issue=6 |pages=1054–62; quiz 1063–4 |date=December 2008 |pmid=19084106 |doi=10.1016/j.jaci.2008.10.023 |url=}}</ref>
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Wiskott-Aldrich syndrome]]
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* Positive family history
* Positive family history
Line 269: Line 269:
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Acquired Disorders of [[Platelet]] Function<span name="harr_c115s002s004s002p001"></span><span name="9100808"></span>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Acquired Disorders of [[Platelet]] Function<span name="harr_c115s002s004s002p001"></span><span name="9100808"></span>
| align="left" style="background:#F5F5F5 |
| align="left" style="background:#F5F5F5 " |
* [[Chronic renal failure pathophysiology|Uremia]]
* [[Chronic renal failure pathophysiology|Uremia]]
* [[Cardiopulmonary bypass]]
* [[Cardiopulmonary bypass]]
Line 286: Line 286:
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Von Willebrand disease|Von Willebrand Disease]]<span name="harr_c115s002s005p001"></span><span name="9100810"></span> <ref name="pmid25196510">{{cite journal |vauthors=Elbatarny M, Mollah S, Grabell J, Bae S, Deforest M, Tuttle A, Hopman W, Clark DS, Mauer AC, Bowman M, Riddel J, Christopherson PA, Montgomery RR, Rand ML, Coller B, James PD |title=Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project |journal=Haemophilia |volume=20 |issue=6 |pages=831–5 |date=November 2014 |pmid=25196510 |pmc=4251588 |doi=10.1111/hae.12503 |url=}}</ref><ref name="pmid25196510">{{cite journal |vauthors=Elbatarny M, Mollah S, Grabell J, Bae S, Deforest M, Tuttle A, Hopman W, Clark DS, Mauer AC, Bowman M, Riddel J, Christopherson PA, Montgomery RR, Rand ML, Coller B, James PD |title=Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project |journal=Haemophilia |volume=20 |issue=6 |pages=831–5 |date=November 2014 |pmid=25196510 |pmc=4251588 |doi=10.1111/hae.12503 |url=}}</ref><ref name="pmid16985174">{{cite journal |vauthors=Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Hashemi Soteh M, Baronciani L, Hallden C, Guilliatt A, Lester W, Peake I |title=Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD) |journal=Blood |volume=109 |issue=1 |pages=112–21 |date=January 2007 |pmid=16985174 |doi=10.1182/blood-2006-05-020784 |url=}}</ref><ref name="pmid9579642">{{cite journal |vauthors=Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ |title=PFA-100 system: a new method for assessment of platelet dysfunction |journal=Semin. Thromb. Hemost. |volume=24 |issue=2 |pages=195–202 |date=1998 |pmid=9579642 |doi=10.1055/s-2007-995840 |url=}}</ref><ref name="pmid258585642">{{cite journal |vauthors=Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J |title=Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH |journal=J. Thromb. Haemost. |volume=13 |issue=7 |pages=1345–50 |date=July 2015 |pmid=25858564 |pmc=5576173 |doi=10.1111/jth.12964 |url=}}</ref>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Von Willebrand disease|Von Willebrand Disease]]<span name="harr_c115s002s005p001"></span><span name="9100810"></span> <ref name="pmid25196510">{{cite journal |vauthors=Elbatarny M, Mollah S, Grabell J, Bae S, Deforest M, Tuttle A, Hopman W, Clark DS, Mauer AC, Bowman M, Riddel J, Christopherson PA, Montgomery RR, Rand ML, Coller B, James PD |title=Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project |journal=Haemophilia |volume=20 |issue=6 |pages=831–5 |date=November 2014 |pmid=25196510 |pmc=4251588 |doi=10.1111/hae.12503 |url=}}</ref>
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* Easy bruising
* Easy bruising
Line 308: Line 308:
|-
|-
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Vessel wall disorders
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Vessel wall disorders
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Metabolism|Metabolic]] and [[Inflammation|Inflammatory]] Disorders
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Metabolism|Metabolic]] and [[Inflammation|Inflammatory]] Disorders
! align="left" style="padding: 5px 5px; background: #DCDCDC;" |
! colspan="2" |
* Acute febrile illnesses
* Acute febrile illnesses
* [[Cryoglobulinemia|Mixed cryoglobulinemia]]
* [[Cryoglobulinemia|Mixed cryoglobulinemia]]
Line 334: Line 334:
|<nowiki>-</nowiki>
|<nowiki>-</nowiki>
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited Disorders of the [[Vessel wall|Vessel Wall]]
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited Disorders of the [[Vessel wall|Vessel Wall]]
! align="left" style="padding: 5px 5px; background: #DCDCDC;" |
! colspan="2" |
* [[Marfan's syndrome|Marfan’s syndrome]]
* [[Marfan's syndrome|Marfan’s syndrome]]
* [[Ehlers-Danlos syndrome]]
* [[Ehlers-Danlos syndrome]]
Line 355: Line 355:
|<nowiki>-</nowiki>
|<nowiki>-</nowiki>
|-
|-
! rowspan="12" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Coagulation factor disorders<ref name="pmid29027765">{{cite journal |vauthors=Karimi M, Peyvandi F, Naderi M, Shapiro A |title=Factor XIII deficiency diagnosis: Challenges and tools |journal=Int J Lab Hematol |volume=40 |issue=1 |pages=3–11 |date=February 2018 |pmid=29027765 |doi=10.1111/ijlh.12756 |url=}}</ref><ref name="pmid27590165">{{cite journal |vauthors=Peyvandi F, Garagiola I, Biguzzi E |title=Advances in the treatment of bleeding disorders |journal=J. Thromb. Haemost. |volume=14 |issue=11 |pages=2095–2106 |date=November 2016 |pmid=27590165 |doi=10.1111/jth.13491 |url=}}</ref><ref name="pmid28966616">{{cite journal |vauthors=Bender L, Weidmann H, Rose-John S, Renné T, Long AT |title=Factor XII-Driven Inflammatory Reactions with Implications for Anaphylaxis |journal=Front Immunol |volume=8 |issue= |pages=1115 |date=2017 |pmid=28966616 |pmc=5605561 |doi=10.3389/fimmu.2017.01115 |url=}}</ref><ref name="pmid28966616" /><ref name="pmid27380557">{{cite journal |vauthors=Schmaier AH |title=Antithrombotic potential of the contact activation pathway |journal=Curr. Opin. Hematol. |volume=23 |issue=5 |pages=445–52 |date=September 2016 |pmid=27380557 |pmc=5148823 |doi=10.1097/MOH.0000000000000271 |url=}}</ref><ref name="pmid26565070">{{cite journal |vauthors=Schmaier AH |title=The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities |journal=J. Thromb. Haemost. |volume=14 |issue=1 |pages=28–39 |date=January 2016 |pmid=26565070 |doi=10.1111/jth.13194 |url=}}</ref><ref name="pmid20580091">{{cite journal |vauthors=Kaplan AP, Ghebrehiwet B |title=The plasma bradykinin-forming pathways and its interrelationships with complement |journal=Mol. Immunol. |volume=47 |issue=13 |pages=2161–9 |date=August 2010 |pmid=20580091 |doi=10.1016/j.molimm.2010.05.010 |url=}}</ref><ref name="pmid22185738">{{cite journal |vauthors=Zuraw BL, Christiansen SC |title=Pathophysiology of hereditary angioedema |journal=Am J Rhinol Allergy |volume=25 |issue=6 |pages=373–8 |date=2011 |pmid=22185738 |doi=10.2500/ajra.2011.25.3661 |url=}}</ref><ref name="pmid23629422">{{cite journal |vauthors=Quail MT |title=Prekallikrein deficiency |journal=J Pediatr Oncol Nurs |volume=30 |issue=4 |pages=198–204 |date=2013 |pmid=23629422 |doi=10.1177/1043454213487436 |url=}}</ref><ref name="pmid27894217">{{cite journal |vauthors=Dorgalaleh A, Alavi SE, Tabibian S, Soori S, Moradi E, Bamedi T, Asadi M, Jalalvand M, Shamsizadeh M |title=Diagnosis, clinical manifestations and management of rare bleeding disorders in Iran |journal=Hematology |volume=22 |issue=4 |pages=224–230 |date=May 2017 |pmid=27894217 |doi=10.1080/10245332.2016.1263007 |url=}}</ref><ref name="pmid29483100">{{cite journal |vauthors=Maas C, Renné T |title=Coagulation factor XII in thrombosis and inflammation |journal=Blood |volume=131 |issue=17 |pages=1903–1909 |date=April 2018 |pmid=29483100 |doi=10.1182/blood-2017-04-569111 |url=}}</ref>
! rowspan="12" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Coagulation factor disorders
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Fibrinogen]] deficiency<ref name="pmid29844251">{{cite journal |vauthors=Tiscia GL, Margaglione M |title=Human Fibrinogen: Molecular and Genetic Aspects of Congenital Disorders |journal=Int J Mol Sci |volume=19 |issue=6 |pages= |date=May 2018 |pmid=29844251 |pmc=6032319 |doi=10.3390/ijms19061597 |url=}}</ref>
<ref name="pmid28966616" />
! style="padding: 5px 5px; background: #DCDCDC;" |Different types of the [[fibrinogen]] disorders:
! align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Fibrinogen]] deficiency
! colspan="2" |Different types of the [[fibrinogen]] disorders:
* [[Fibrinogen#Congenital afibrinogenemia|Congenital afibrinogenemia]]
* [[Fibrinogen#Congenital afibrinogenemia|Congenital afibrinogenemia]]
* [[Fibrinogen#Congenital hypofibrinogenemia|Congenital hypofibrinogenemia]]
* [[Fibrinogen#Congenital hypofibrinogenemia|Congenital hypofibrinogenemia]]
Line 536: Line 537:
|
|
|-
|-
! colspan="2" rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor XIII deficiency]]
! rowspan="1" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Factor XIII deficiency]]
! style="padding: 5px 5px; background: #DCDCDC;" |Types:
! colspan="2" |Types:
* Sub unit A mutation disease (more common)
* Sub unit A mutation disease (more common)
* Sub unit B mutation disease
* Sub unit B mutation disease
Line 557: Line 558:
* The severity of factor XIII deficiency bleeds can be different in different patients  
* The severity of factor XIII deficiency bleeds can be different in different patients  
|-
|-
! rowspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemophilia]]<ref name="pmid94489952">{{cite journal |vauthors=Aviña-Zubieta JA, Galindo-Rodriguez G, Lavalle C |title=Rheumatic manifestations of hematologic disorders |journal=Curr Opin Rheumatol |volume=10 |issue=1 |pages=86–90 |date=January 1998 |pmid=9448995 |doi= |url=}}</ref><ref name="pmid16551972">{{cite journal |vauthors=Plug I, Mauser-Bunschoten EP, Bröcker-Vriends AH, van Amstel HK, van der Bom JG, van Diemen-Homan JE, Willemse J, Rosendaal FR |title=Bleeding in carriers of hemophilia |journal=Blood |volume=108 |issue=1 |pages=52–6 |date=July 2006 |pmid=16551972 |doi=10.1182/blood-2005-09-3879 |url=}}</ref><ref name="pmid25059285">{{cite journal |vauthors=Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A |title=Definitions in hemophilia: communication from the SSC of the ISTH |journal=J. Thromb. Haemost. |volume=12 |issue=11 |pages=1935–9 |date=November 2014 |pmid=25059285 |doi=10.1111/jth.12672 |url=}}</ref><ref name="pmid11307831">{{cite journal |vauthors=White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J |title=Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis |journal=Thromb. Haemost. |volume=85 |issue=3 |pages=560 |date=March 2001 |pmid=11307831 |doi= |url=}}</ref><ref name="pmid24026910">{{cite journal |vauthors=Favaloro EJ, Meijer P, Jennings I, Sioufi J, Bonar RA, Kitchen DP, Kershaw G, Lippi G |title=Problems and solutions in laboratory testing for hemophilia |journal=Semin. Thromb. Hemost. |volume=39 |issue=7 |pages=816–33 |date=October 2013 |pmid=24026910 |doi=10.1055/s-0033-1356573 |url=}}</ref><ref name="pmid250592852">{{cite journal |vauthors=Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A |title=Definitions in hemophilia: communication from the SSC of the ISTH |journal=J. Thromb. Haemost. |volume=12 |issue=11 |pages=1935–9 |date=November 2014 |pmid=25059285 |doi=10.1111/jth.12672 |url=}}</ref>
! rowspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemophilia]]


! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type A deficiency
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Type A deficiency
Line 617: Line 618:
|-
|-
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rare diseases
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rare diseases
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Disseminated intravascular coagulation|Disseminated Intravascular Coagulation]]<ref name="pmid30008620">{{cite journal |vauthors=Wada H, Matsumoto T, Suzuki K, Imai H, Katayama N, Iba T, Matsumoto M |title=Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy |journal=Thromb J |volume=16 |issue= |pages=14 |date=2018 |pmid=30008620 |pmc=6040080 |doi=10.1186/s12959-018-0168-2 |url=}}</ref>
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Disseminated intravascular coagulation|Disseminated Intravascular Coagulation]]
! style="padding: 5px 5px; background: #DCDCDC;" |
!
* [[Trauma]]
* [[Trauma]]
* Burn  
* Burn  
Line 639: Line 640:
| -
| -
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Vitamin K Deficiency]]<ref name="pmid26314836">{{cite journal |vauthors=Shiraishi E, Iijima H, Shinzaki S, Nakajima S, Inoue T, Hiyama S, Kawai S, Araki M, Yamaguchi T, Hayashi Y, Fujii H, Nishida T, Tsujii M, Takehara T |title=Vitamin K deficiency leads to exacerbation of murine dextran sulfate sodium-induced colitis |journal=J. Gastroenterol. |volume=51 |issue=4 |pages=346–56 |date=April 2016 |pmid=26314836 |doi=10.1007/s00535-015-1112-x |url=}}</ref>
! colspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Vitamin K Deficiency]]
! style="padding: 5px 5px; background: #DCDCDC;" |
!
* Bleeding after trauma
* Bleeding after trauma
* [[Epistaxis]]
* [[Epistaxis]]
Line 663: Line 664:
| -
| -
|}
|}
Different types of Von-Willebrand diseases can be differentiated from each other based on the following table:<ref name="pmid258585643">{{cite journal |vauthors=Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J |title=Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH |journal=J. Thromb. Haemost. |volume=13 |issue=7 |pages=1345–50 |date=July 2015 |pmid=25858564 |pmc=5576173 |doi=10.1111/jth.12964 |url=}}</ref>
Different types of Von-Willebrand diseases can be differentiated from each other based on the following table:


{|
{|
Line 686: Line 687:
|-
|-
! rowspan="4" align="center" style="background:#DCDCDC;" |Type 2
! rowspan="4" align="center" style="background:#DCDCDC;" |Type 2
! align="center" style="background:#DCDCDC;" |2A<ref name="pmid1537829">{{cite journal |vauthors=Lyons SE, Bruck ME, Bowie EJ, Ginsburg D |title=Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations |journal=J. Biol. Chem. |volume=267 |issue=7 |pages=4424–30 |date=March 1992 |pmid=1537829 |doi= |url=}}</ref>
! align="center" style="background:#DCDCDC;" |2A
| align="center" style="background:#F5F5F5;" | Qualitative
| align="center" style="background:#F5F5F5;" | Qualitative
| align="center" style="background:#F5F5F5;" | 10%
| align="center" style="background:#F5F5F5;" | 10%
Line 739: Line 740:
|}
|}
For more information on Von Willebrand disease, click [[ von willebrand disease | here]].
For more information on Von Willebrand disease, click [[ von willebrand disease | here]].
<references />

Revision as of 15:54, 19 October 2018

Differential Diagnosis

Different causes of the bleeding disorders can be differentiated based on their clinical manifestation and laboratory findings.

These features have discussed in the below table:

Category Sub-category Diseases History Clinical manifestation Laboratory testing Comments
Mucosal bleeding Petechia Ecchymoses Menorrhagia Hematoma Hemarthrosis Platelet count Bleeding time (BT) Prothrombin time (PT) Activated partial thromboplastin time (aPTT) Thrombin time (TT)
Platelet disorders Thrombocytopenia Infection-Induced thrombocytopenia
  • History of prior infection
+ + + + + + Normal Normal Normal
Medications-Induced thrombocytopenia + + + + + + Normal Normal Normal Most important part of treatment is discontinuing of the medication.
Heparin-Induced thrombocytopenia + + + + + + Normal Normal For more information click here: Heparin-induced thrombocytopenia.
Immune Thrombocytopenic Purpura (ITP) + + + + + + Normal Normal Normal
Inherited Thrombocytopenia
  • Positive family history
+ + + + + + Normal Normal Normal
Thrombotic Thrombocytopenic Purpura (TTP) History of: + + + + + + Normal Normal Normal
Hemolytic Uremic Syndrome History of: + + + + + + Normal Normal Normal
Thromobcytosis Iron deficiency anemia

Inflammatory diseases

Splenectomy

Essential thrombocytosis

+/- +/- Normal or ↑ Normal Normal Normal
Qualitative Disorders of Platelet Function Inherited Disorders of Platelet Function Glanzmann’s thrombasthenia
  • Positive family history
+ + + + Rare Normal or ↓ Normal Normal Normal
  • AR inheritance
  • Absence of the platelet Gp IIb/IIIa receptor
  • Diminished for GP 2B-3A on flow cytometry
Bernard-Soulier syndrome
  • Positive family history
+ + + + Normal/↓ Normal Normal Normal
  • AR inheritance
  • Absence of the platelet Gp Ib-IX-V receptor
  • On PBS: giant platelets
  • Ristocetin - no aggregation
Wiskott-Aldrich syndrome
  • Positive family history
+ + + + Normal or ↓ Normal Normal Normal
  • Anti-WASP antibody can be used to detect presence or absence of WAS protein
  • In Wiskott–Aldrich syndrome, the platelets are small and do not function properly. They are removed by the spleen, which leads to low platelet counts.
Platelet storage pool disorder (SPD): + + + + Normal or ↓ Normal Normal Normal
  • AD inheritance
  • Abnormalities of platelet granule formation
Acquired Disorders of Platelet Function + + + + +/- +/- Normal/↓ Normal Normal Normal
Von Willebrand Disease [1] + + + + +/- +/- Normal Normal See the table below for the details about different types.
Vessel wall disorders Metabolic and Inflammatory Disorders
  • History of the underlying disease.
+ + +/- - - Normal ↑/Normal Normal Normal Normal -
Inherited Disorders of the Vessel Wall
  • Positive family history
- + + +/- - - Normal ↑/Normal Normal Normal Normal -
Coagulation factor disorders

[2]

Fibrinogen deficiency Different types of the fibrinogen disorders: - - + + +/- + Normal
  • Impaired fibrin cross linking or clot dissolution.
  • The severity of bleeding in patients with fibrinogen disorders can be mild or severe, with higher bleeding risk in those with afibrinogenemia or lower levels of functional fibrinogen. The age of onset is also variable, with earlier onset in those with more severe deficiency.
Prothrombin deficiency + + + + + Normal Normal -
Factor V deficiency _ + + + + Normal Normal The severity of bleeding is only partly related to the degree of factor V deficiency. Some patients with undetectable plasma levels of factor V experience only relatively mild bleeding.
Factor VII deficiency + + + Normal Normal Normal Thrombosis occurs in inherited factor VII deficiency most cases are associated with the administration of factor VII replacement therapy
Factor X deficiency
  • Prolonged bleeding following circumcision
+ + + + + Normal Normal Normal -
Factor XII deficiency
  • Majority,asymptomatic
  • Recurrent miscarriages
  • Painful leg ulcers
_ _ _ _ _ Normal Normal Normal Normal
High molecular weight kininogen (HMWK) deficiency
  • Possibility of positive family history of bleeding
_ _ _ _ _ Normal Normal Normal Normal
Prekallikrein deficiency
  • Possibility of positive family history of bleeding
_ _ _ _ _ Normal Normal Normal Normal
Factor XIII deficiency Types:
  • Sub unit A mutation disease (more common)
  • Sub unit B mutation disease
  • Possibility of positive family history of bleeding
-/+ -/+ -/+ -/+ -/+ -/+ Normal Normal Normal/↑ Normal Normal
  • Impaired fibrin cross linking or clot dissolution
  • The severity of factor XIII deficiency bleeds can be different in different patients
Hemophilia Type A deficiency - - - + + + Normal Normal Normal Normal -
Type B deficiency - - - + + + Normal Normal Normal Normal -
Type C deficiency
  • Family history
  • Bleeding after surgery or injury
- - - + Rare Rare Normal Normal Normal Normal -
Rare diseases Disseminated Intravascular Coagulation + + + + + + Normal -
Vitamin K Deficiency + - + + + + Normal Normal or mildly prolonged Normal -

Different types of Von-Willebrand diseases can be differentiated from each other based on the following table:

Type of VWD Type of factor deficiency Prevalence Inheritance pattern Clinical manifestations VWF activity RIPA Factor VIII
Type 1 Quantitative/ partial 60-70% AD
  • Bleeding severity mild to severe
Type 2 2A Qualitative 10% AD/AR N or ↓
2B Qualitative 5% AD N or ↓
2M Qualitative <1% AD/AR N or ↓
2N Qualitative <1% AR N N
Type 3 Complete deficiency 1-2% AR Absent Low, 1-10%

For more information on Von Willebrand disease, click here.

  1. Elbatarny M, Mollah S, Grabell J, Bae S, Deforest M, Tuttle A, Hopman W, Clark DS, Mauer AC, Bowman M, Riddel J, Christopherson PA, Montgomery RR, Rand ML, Coller B, James PD (November 2014). "Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project". Haemophilia. 20 (6): 831–5. doi:10.1111/hae.12503. PMC 4251588. PMID 25196510.
  2. Invalid <ref> tag; no text was provided for refs named pmid28966616